• Passa al contenuto principale
BC

biochimica clinica

it_IT Italian
it_IT Italian en_US English
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

EDITORIALI - Editorials

Volume:

Biochimica Clinica 2019; 43(2) e12-e16

Pubblicato on-line:

Aprile 16, 2019

DOI:

10.19186/BC_2019.028

Scarica in PDF:
Autenticazione richiesta

Un effettivo vantaggio dello screening neonatale allargato

AUTORI

Cristina Mazzaccara1,2, Adriana Redi1, Lucia Albano2, Simona Fecarotta3, Carmen Flagiello2, Daniela Crisci2, Fabio Acquaviva3, Giovanna Gallo2, Antonio Nolano1, Bruno Mirra1, Rita Pecce1, Giancarlo Parenti3, Guglielmo Rosario Domenico Villani1,2, Margherita Ruoppolo1,2, Giulia Frisso1,2
1Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Napoli;
2CEINGE Biotecnologie Avanzate, s.c.a r.l., Napoli;
3Dipartimento di Medicina Translazionale-Sezione di Pediatria, Università degli Studi di Napoli Federico II.

ABSTRACT

A real benefit of an extended neonatal screening

Methylenetetrahydrofolate Reductase (MTHFR) deficiency, is avery rare congenital defect of folate metabolism, inherited in an autosomal recessive pattern included in newbornscreening (NBS) programs in Italy. It is caused by mutations in the MTHFRgene and is characterized by elevatedplasma homocysteine and borderline-low or normal methionine levels, causing severe neurological signs, recurrentapnoea, microcephaly and convulsions, generally during the neonatal period. An early treatment may prevent theclinical manifestations with a positive impact on patient’s health.
We report a new case of MTHFRdeficiency, identified during NBS that showed hypomethioninemia 4.6 μmol/L (r.i.6-20). The second level-test revealed hyperhomocysteinemia (106.7 μM, r.i. 5-15). The whole sequencing of theMTHFRgene showed two missense mutation: c.176G>C (p.Trp59Ser), reported as disease causing and the novelc.1769T>G (p.Leu590Arg), classified as likely pathogenetic. The baby was immediately treated with vitamin B12,folate and betaine; after 12 months of follow-up he has no signs or symptoms of the disease.
In conclusion, this case report highlights the importance of NBS for inborn errors of metabolism and genetic analysis,that can prevent the establishment of a serious disorder of folate metabolism.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967